CVD

Genomics plc publishes clinical trial results demonstrating successful integration and clinical utility of integrated risk scores combining polygenic and clinical risk of cardiovascular disease in NHS primary care

Retrieved on: 
Wednesday, January 31, 2024
NHS health check, GP, CVD, Cholesterol, Genetics, Knowledge, Family, IRT, Heart, FRS, Cardiovascular disease, Clinical trial, Risk assessment, BMI, Patient, Ageing, Friends, Durham University, NHS, European Journal, Risk, PRS, National Health Service, Blood pressure, Absolute risk

The HEART Study is the world's first clinical trial investigating the use of genomic 'polygenic risk score (PRS) testing' to support the prevention of cardiovascular disease (CVD) in National Health Service (NHS) clinical practice.

Key Points: 
  • The HEART Study is the world's first clinical trial investigating the use of genomic 'polygenic risk score (PRS) testing' to support the prevention of cardiovascular disease (CVD) in National Health Service (NHS) clinical practice.
  • It was designed to evaluate an integrated risk tool (IRT) that combines genetic risk in the form of a polygenic risk score or PRS, with QRISK, a prediction algorithm for CVD.
  • For people aged 45-64, genetics accounts for 40% as much risk as all the non-genetic risk factors combined in QRISK.
  • We hope that it will also encourage similar studies incorporating genetics into clinical risk prediction for other common diseases."

New Survey Reveals 86 Percent of Benefits Leaders Recognize Need for Heart Health Strategy in 2024

Retrieved on: 
Tuesday, January 23, 2024
Health, Apps, Applications, Technology, Software, General Health, Cardiology, Death, System, Artificial intelligence, Woman, Heart, Health equity, Sleep apnea, CVD, Stroke, Heart failure, Risk, Organization, Kidney disease, Moyamoya disease, Hispanic, Splenic infarction, Cholesterol, African Americans, Cardiovascular disease, Blood pressure, SVP, Dietary supplement

Hello Heart , the digital leader in preventive heart health, today released its inaugural Why Heart Health Matters Report , which examines the toll that cardiovascular disease (CVD) takes on employers, health plans, and the people they serve.

Key Points: 
  • Hello Heart , the digital leader in preventive heart health, today released its inaugural Why Heart Health Matters Report , which examines the toll that cardiovascular disease (CVD) takes on employers, health plans, and the people they serve.
  • The report surveyed 300 benefits leaders at large employers and health plans to gauge their investment and prioritization of member health initiatives for 2024.
  • As a result, organizations increasingly recognize heart health as a business need, with 76 percent listing it among their top three strategic organizational health priorities for 2024.
  • The Why Heart Health Matters Report shows that 86 percent of benefits leaders at large employers and health plans recognize the need for an organizational strategy to address heart health.

Supportive, Stable Caregiving in Childhood Protects Heart Health in Adulthood

Retrieved on: 
Tuesday, January 23, 2024
CARDIA, Hope, Pediatrics, American Heart Association, Death, Population health, NYU Langone Health, Risk, Research, Overalls, Physiology, Health, Life, Smoking, Diet, CVD, University, Lipid, Behavior, Ageing, PHD, MHS, NYU, Safety, White, Caregiver, Cardiovascular disease, Child, University of California, Circulation (journal), Popliteal artery entrapment syndrome, University of Pennsylvania, Kidney, CVH, MPH, Black, Endocrine Society, Digestive, Saint Andrew's Society, Blood pressure, Lung

New research, however, shows that receiving warmth from a caregiver during childhood protects cardiovascular health later in life, according to a study led by NYU Grossman School of Medicine and The Ohio State University Wexler Medical Center.

Key Points: 
  • New research, however, shows that receiving warmth from a caregiver during childhood protects cardiovascular health later in life, according to a study led by NYU Grossman School of Medicine and The Ohio State University Wexler Medical Center.
  • "At the same time, our findings show that adversity in early childhood does not equal destiny.
  • While adverse childhood family environments were associated with lower odds of cardiovascular health in adulthood, our findings suggest that supportive and, importantly, stable caregiving may have a stronger influence on later heart health than early adversity."
  • The hope, says Ortiz, is that this study offers insight into how supporting healthy, both supportive and stable, caregiving relationships in childhood can offer greater attainment of CVH at a population level.

CORBEVAX®, A COVID19 VACCINE DEVELOPED BY BIO E-INDIA BASED ON THE RBD PROTEIN ANTIGEN TECHNOLOGY FROM TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT, RECEIVES WORLD HEALTH ORGANIZATION EMERGENCY USE LISTING APPROVAL

Retrieved on: 
Monday, January 22, 2024
COVAXIN, World Health Organization, Texas Children's Hospital, UNICEF, COVID19, Tropical medicine, Dean (education), EUL, Medicine, DRS, CVD, BCM, National academy, Baylor College of Medicine, UN, RBD, Baylor University, GMP, Good, CDSCO, Dean, WHO, Safety, COVID-19, Hospital, Biomedical Research, Good manufacturing practice, Nobel Peace Prize, Alum, Vaccine, DCGI, SARS-CoV-2, National school, Biology

HOUSTON, Jan. 22, 2024 /PRNewswire/ -- Texas Children's Hospital announces today that Biological E's CORBEVAX®, a traditional, recombinant protein-based COVID-19 vaccine has received World Health Organization (WHO) approval under Emergency Use Listing (EUL). CORBEVAX® is developed and commercialized by Biological E Limited, an established global vaccine supplier based in Hyderabad, India, using Pichia pastoris yeast strain expressing Receptor Binding Domain (RBD) protein of SARS-CoV-2 engineered by Texas Children's Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine (BCM),

Key Points: 
  • "The recombinant yeast strains enable production of the RBD protein which can be further utilized by vaccine researchers globally to develop & manufacture effective and low-cost vaccines.
  • By providing access to the yeast strains via non-exclusive licensing, we continue our mission to support global vaccine accessibility and availability."
  • Biological E subsequently developed large scale manufacturing technology for production of the RBD protein complying with Good Manufacturing Practices (GMP) as well as testing & characterization suitable for use as vaccine antigen.
  • The RBD protein was then used as an antigen and formulated with optimized adjuvants (Alum and CpG1018) to develop a COVID-19 candidate vaccine.

Synthetic Diamond Market Comprehensive Global and Regional Analysis (2023-2032)

Retrieved on: 
Thursday, January 18, 2024
Diamond, Synthetic, Region, Jewellery, CVD, HPHT, Electronics, Name, Mining, Chemical vapor deposition

DUBLIN, Jan. 17, 2024 /PRNewswire/ -- The "Synthetic Diamond Market - A Global and Regional Analysis: Focus on Applications, Type, Manufacturing Process, and Region - Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 17, 2024 /PRNewswire/ -- The "Synthetic Diamond Market - A Global and Regional Analysis: Focus on Applications, Type, Manufacturing Process, and Region - Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.
  • The synthetic diamond market is witnessing a significant upsurge driven by technological advancements, sustainability concerns, and a broadening spectrum of applications.
  • This new analysis captures the industry's trajectory, focusing on global and regional insights that are geared towards stakeholders looking for data-driven insights and forecasts.
  • This comprehensive report segments the market by application, type, manufacturing process, and region.

Global Portable Ultrasound Equipment Strategic Analysis Report 2023: Market to Reach $2.9 Billion by 2030 - A Bright Star of Evolutionary Journey of Ultrasound Technology - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024
Health, Medical Supplies, Medical Devices, Stroke, CVD, Central Statistics Office (India), Statistics, Incidence, Cardiovascular disease, Fatality

Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050

Key Points: 
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    Global Annual Medical Cost of CVD in US$ Billion: 2010, 2015, 2020, 2025 and 2030
    Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    World Diabetes and Population Statistics (2019, 2030 & 2045)
    Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others

Global Clinical Trial Supplies Markets 2023-2028 by Services (Manufacturing, Packaging, Logistics), Phases, Type (Small Molecules, Biologics), Therapeutic Areas (Oncology, CVD, Infectious, Immunology) - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024
Pharmaceutical, Health, Clinical Trials, Medical Supplies, ChromeOS, Oncology, CVD, Infection, COVID-19, USD, Molecule, Region, Clinical trial, Prevalence, Growth, Pharmaceutical industry

The global clinical trial supplies market is projected to reach USD 6.3 billion by 2028 from USD 3.9 billion in 2023, at a CAGR of 9.9%.

Key Points: 
  • The global clinical trial supplies market is projected to reach USD 6.3 billion by 2028 from USD 3.9 billion in 2023, at a CAGR of 9.9%.
  • The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial supplies market and its subsegments.
  • Based on services, the global clinical trial supplies market is segmented into pathogen component, adjuvant emulsions, particulate adjuvants, saponin-based adjuvants and other adjuvants.
  • Based on phase, the clinical trial supplies market is segmented into phase I, phase II, phase III, phase IV, BA/BE studies.

Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™

Retrieved on: 
Thursday, January 4, 2024
Technology, Insurance, Human Resources, Health Technology, Professional Services, Cardiology, Health Insurance, Health, Data Management, Artificial Intelligence, Workforce, CDC, Entrepreneurship, Spouse, Risk, Health care, United States Census Bureau, Smoking, Moyamoya disease, Conditional sentence, Diabetes, CHD, Stroke, CVD, Absenteeism, Biomarker, Morale, Diagnosis, Cardiovascular disease

Chronic conditions, including cardiovascular disease, significantly impact healthcare costs for employers.

Key Points: 
  • Chronic conditions, including cardiovascular disease, significantly impact healthcare costs for employers.
  • According to United Healthcare, heart disease and stroke alone cost employers $363 billion annually.
  • The Company’s most recent heart disease fair for an employer organization gained participation from 75% of eligible employees and their spouses .
  • "As we serve providers, health plans, and employer organizations, we know that the human toll and financial costs of cardiovascular disease are integrated.

NewAmsterdam Pharma Announces 2024 Strategic Priorities

Retrieved on: 
Thursday, January 4, 2024
Well, ASCVD, Dyslipidemia, Marketing, Apolipoprotein B, Risk, NAMS, Physician, Apolipoprotein, Moyamoya disease, Mortality, Clinical trial, CVD, Phase 3, FDC, Patient, Safety, Cardiovascular disease, Ezetimibe, History, Pharmaceutical industry

-- Well-capitalized with cash to support operations through BROADWAY, BROOKLYN, and PREVAIL readouts --

Key Points: 
  • “NewAmsterdam is entering 2024 on the precipice of a major transformation, with the potential to deliver significant benefit to patients globally and create value for our shareholders,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam.
  • NewAmsterdam completed enrollment of approximately 350 patients in April 2023 and expects to report topline data in the third quarter of 2024.
  • NewAmsterdam completed enrollment of over 2,500 patients in July 2023 and expects to report topline data in the fourth quarter of 2024.
  • NewAmsterdam expects to complete patient enrollment in PREVAIL in the first quarter of 2024 and to report topline data in 2026.

New Guidelines on Men with Erectile Dysfunction and Cardiac Health Published in the Journal of Sexual Medicine Concludes PDE-5 Inhibitors are Still Safe for the Cardiovascular System

Retrieved on: 
Thursday, January 4, 2024
Research, Seniors, Men, Cardiology, Biotechnology, Health, Consumer, Pharmaceutical, Science, Patient, Exercise, HMRI, ED, Risk, Nitrate, Woman, PDE5, Hypotension, Moyamoya disease, B cell, Mortality, Regenerative medicine, Pharmacist, Platelet-rich plasma, MBA, MD, Doctor of Philosophy, Huntington Medical Research Institutes, Pulmonary hypertension, Tadalafil, University, CVD, Death, CAC, System, CT scan, Oxygen, American College, Contra, Overalls, Dietary supplement, Princeton University, Ischemia, Journal, Female, Johns Hopkins, Erectile dysfunction, Pharmaceutical industry

Their summary and guidelines have now been published in the Journal of Sexual Medicine.

Key Points: 
  • Their summary and guidelines have now been published in the Journal of Sexual Medicine.
  • They determined that PDE-5 inhibitors are still safe for the cardiovascular system.
  • The conference was funded by an unrestricted grant from Sanofi to readdress the cardiovascular workup of men presenting with ED and the cardiovascular safety of the phosphodiesterase-5 (PDE-5) inhibitors for treating ED.
  • Patients with ED should be characterized as low-risk, intermediate (or indeterminable), or high-risk of developing a cardiac event with sexual activity.